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156 Poster Session-IImofetil (MMF) starting day -1. On day 17, the patient received an
accidental dose of HIDAC 3700 mg/m2 (6000mg) over 3 hours
instead of MMF. Patient developed worsening of her nausea and
vomitting but was controlled with antiemetics. She engrafted her
neutrophils with her absolute neutrophil count (ANC) .500/ml on
day 133 and .1000/ml on day 135 post SCT. She engrafted her
platelets with her untransfused platelet count . 20,000/ml on day
143 and.50,000/ml on day154 post SCT. Patient did not develop
any acute gvhd. On day 136 the patient was discharged from the
hospital. Patient had CNS relapse on day 171 (positive CSF cytol-
ogy and leptomeningeal enhancement on an MRI) but no systemic
disease (bone marrow biopsy 99–100% donor chimerisim and nor-
mal cytogenetics). The patient’s treatment included intrathechal li-
posomal cytarabine 50 mg on day 172 and 196, HIDAC 3000
mg/m2 every 12 hours for 10 doses from day 177 to 182 and dasa-
tinib 140 mg orally daily from day178 to183. Tacrolimus was dis-
continued on day177. The patient was neutropenic for 37 days (day
184 to1120) but achieved a remission in her CNS. At day1175 pa-
tient is alive, disease free, without gvhd off all immunosuppression
with normal ANC with 100 percent donor chimerism.
Discussion: There is no literature on HIDAC infusion post allo-
geneic SCT. Published data suggests that the longer duration of cy-
tarabine exposure is more cytotoxic to hematopoietic cells than the
dose. Other chemotherapeutic agents including methotrexate and
cyclophosphamide has been given posttransplantation for gvhd pro-
phylaxis and graft enhancement. HIDAC infusion post CBSCT did
not significantly delay neutrophil or platelet engraftment as com-
pared to published literature but may have contributed to lack of
gvhd in this patient inspite of withdrawl of all immunosuppression
by day 177.445
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Hemorrhagic cystitis caused by polyomavirus virus (BKV) is
a common complication following high dose chemotherapy and he-
matopoietic stem cell transplant. Low dose cidofovir has been shown
to be useful in the eradication of BKV post transplantation without
significant side effects. Controversy exists over the effective dose, du-
ration, and administration technique for cidofovir. Recent data
shows utilization of a dose range of 0.25–1mg/kg IV weekly. The
purpose of this review is to establish an optimal dose, duration,
and monitoring standards for cidofovir use in a future prospective
trial. This information will be further utilized at our institution to
implement an evidence- based standard of practice. A retrospective
review was completed on 13 patients with symptomatic BKV who re-
ceived cidofovir during a 15-month period. Cidofovir dose was given
without probenecid and initiated at 0.5mg/kg intravenously weekly.
If no significant reduction in viral copies was seen, the dose was es-
calated to 1mg/kg. Patients were monitored for a molecular response
in both urine and plasma for BK viral load. Molecular response was
defined as a decrease in viral load by one log reduction with a consis-
tent decreasing trend. Patients received cidofovir for an average of
7.6 weeks. Urinary response was shown in 7/13 (54%) and plasma re-
sponse in 6/9 (67%) patients. Plasma PCR data was not measured in
5 patients. Transplant-related mortality occurred in 5 patients with80% (4/5) not responding in the urine to treatment. Acute renal fail-
ure, defined as an increase of 0.5mg/dL from baseline, occurred in 1/
13 (7.6%). Based on this data, we plan to enroll patients into a ran-
domized study using 0.5mg/kg or 1mg/kg weekly intravenous cido-
fovir to determine the most effective treatment regimen for
symptomatic patients while minimizing toxicity. Patients will have
BKV PCR analysis weekly on blood and urine to determine eradica-
tion and optimal length of therapy. Data will be examined to deter-
mine if therapy can be discontinued based on clinical response or
molecular response. Due to the renal dysfunction associated with
cidofovir, serum creatinine will also be monitored. Results from
this trial will be valuable since no current standard of care for BK
viremia exist.446
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Venous-occlusive disease (VOD) and graft-versus-host disease
(GVHD) are devastating complications of allogeneic hematopoietic
stem cell transplants (HSCT). Mortality has been estimated to be as
high as 30% for VOD and 40% for GVHD, which remains the main
cause of morbidity associated with HSCT. The use of prophylactic
ursodiol is believed to provide protection against complications.
However, clinical evidence for the use of this medication is limited
and the duration of therapy has not been established in non-myeloa-
blative pre-transplant regimens. The primary objective of this retro-
spective review is to determine the incidence and severity of VOD
and GVHD in allogeneic HSCT patients not receiving prophylactic
ursodiol. Thirty-four patients that underwent allogeneic HSCT in
2007 who did not receive ursodiol prophylaxis were evaluated. Acute
GVHD was staged as level 0–4 based on quantification of skin rash,
serum bilirubin, and gastrointestinal tract involvement. Chronic
GVHD will be graded as level I-IV based on the degree of skin
and organ involvement and clinical performance status. VOD will
be graded based on the Baltimore criteria which include jaundice
(bilirubin$ 2.0 mg/dL) and two of the following: hepatomegaly, as-
cites or$ 5% weight gain. Chronic GVHD and VOD data is yet to
be determined. Stage of acute GVHD in patients that were evaluated
is shown below in table 1.
Acute GVHD incidence in 34 patients
Grade 0 Grade 1 Grade 2 Grade 3 Grade 426% (n59) 29% (n510) 32% (n511) 8.8% (n53) 3% (n51)Acute GVHD was seen more often in non-myeloablative (average
grade 1.6, n 5 15) versus myeloablative protocols (average grade
1.2, n5 19). The second phase of this trial will evaluate the incidence
of VOD and GVHD in patients who receive prophylactic ursodiol.
This data will be compared to the patient population that did not
receive prophylaxis to determine the outcome. This data will be
helpful in determining the effectiveness of prophylactic ursodiol in
non-myeloablative HSCT.
